This study therefore suggests for the first time that the treatment with SRLs may modulate the tumor inflammatory infiltrate and confirms that in somatotroph adenomas naïve to pre‐operative SRL treatment, the CD68+/CD8+ ratio was higher in invasive tumors and in those not responsive to post‐surgical SRL therapy. The gene discussed is CD68; the disease is neoplasm.